GlassScriptPhysician profile
Rupa Koothirezhi
NPI 1699207944
$3,723.96
in general payments reported to CMS, 2019-2025
40 companies · $1,377 in 2025
The $1,377 reported for 2025 was more than what 75% of Sleep Medicine (Family Medicine) providers received nationally (typical 2025 total: $557).
See the full distribution for Sleep Medicine (Family Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $46.09 · 2021: $247 · 2022: $670 · 2023: $613 · 2024: $771 · 2025: $1,377.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,660 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,660.46 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $707.41 | 2020-2025 | Xywav |
| Harmony Biosciences LLC | $383.94 | 2021-2025 | Wakix |
| Neurocrine Biosciences, INC. | $298.66 | 2022-2025 | Ingrezza |
| Itamar Medical INC | $266.00 | 2022-2025 | Watchpatone |
| Alexion Pharmaceuticals, INC. | $164.02 | 2021-2024 | Ultomiris, Soliris |
| Avadel Cns Pharmaceuticals, LLC | $158.34 | 2025 | Lumryz |
| Emd Serono, INC. | $153.60 | 2022-2025 | Mavenclad |
| Argenx US, INC. | $133.26 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Inspire Medical Systems, INC. | $110.56 | 2024-2025 | Inspire |
| Novartis Pharmaceuticals Corporation | $103.90 | 2022-2025 | |
| Lilly USA, LLC | $95.46 | 2025 | Zepbound |
| Takeda Pharmaceuticals U.S.A., INC. | $91.55 | 2025 | Glassia, Cuvitru |
| Tanabe Pharma America, INC. | $90.62 | 2023-2024 | |
| Ucb, INC. | $89.48 | 2023-2025 | Briviact, Rystiggo |
| Mallinckrodt Hospital Products INC. | $83.46 | 2023-2025 | Acthar, Terlivaz |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $81.98 | 2025 | Dupixent |
| Biogen, INC. | $79.17 | 2022-2023 | Spinraza, Tysabri, Vumerity |
| Astrazeneca Pharmaceuticals LP | $64.54 | 2025 | Fasenra, Tezspire, Airsupra |
| Lundbeck LLC | $59.50 | 2021-2025 | Rexulti, Vyepti |
| Teva Pharmaceuticals USA, INC. | $43.18 | 2023-2024 | Austedo Xr |
| Eisai INC. | $42.70 | 2022-2024 | |
| Neurelis, INC. | $38.29 | 2024 | Valtoco |
| Idorsia Pharmaceuticals US INC | $36.54 | 2023-2024 | Quviviq |
| Actelion Pharmaceuticals US, INC. | $34.16 | 2025 | Opsynvi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.77 | 2025 | Jascayd |
| Amneal Pharmaceuticals LLC | $27.65 | 2023 | Rytary |
| Averitas Pharma INC. | $26.29 | 2025 | Qutenza |
| Insmed, INC. | $26.15 | 2025 | Brinsupri, Arikayce |
| Merck Sharp & Dohme LLC | $24.01 | 2025 | Winrevair |
| Axsome Therapeutics, INC. | $21.60 | 2025 | Sunosi |
| Genzyme Corporation | $20.89 | 2025 | |
| Zoll Respicardia, INC. | $19.77 | 2023 | Remede System |
| Verona Pharma, INC. | $18.62 | 2025 | Ohtuvayre |
| Biohaven Pharmaceutical Holding Company LTD. | $18.16 | 2022 | |
| Amgen INC. | $16.81 | 2021 | |
| United Therapeutics Corporation | $14.64 | 2025 | Tyvaso |
| Viatris Specialty LLC | $14.31 | 2025 | Yupelri |
| Livanova USA, INC. | $12.46 | 2022 | |
| Mdd US Operations, LLC | $12.46 | 2022 | |
| Arbor Pharmaceuticals, INC. | $12.05 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rupa Koothirezhi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.